company background image
ACUC logo

AcuCort NGM:ACUC Stock Report

Last Price

kr0.50

Market Cap

kr42.3m

7D

22.6%

1Y

-71.2%

Updated

25 Mar, 2024

Data

Company Financials

ACUC Stock Overview

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions.

ACUC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AcuCort AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AcuCort
Historical stock prices
Current Share Pricekr0.50
52 Week Highkr2.05
52 Week Lowkr0.33
Beta0.62
1 Month Change27.27%
3 Month Change28.24%
1 Year Change-71.20%
3 Year Change-89.63%
5 Year Change-92.59%
Change since IPO-89.50%

Recent News & Updates

Recent updates

Shareholder Returns

ACUCSE PharmaceuticalsSE Market
7D22.6%3.7%2.0%
1Y-71.2%80.3%17.8%

Return vs Industry: ACUC underperformed the Swedish Pharmaceuticals industry which returned 80.2% over the past year.

Return vs Market: ACUC underperformed the Swedish Market which returned 18% over the past year.

Price Volatility

Is ACUC's price volatile compared to industry and market?
ACUC volatility
ACUC Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement6.1%
10% most volatile stocks in SE Market13.1%
10% least volatile stocks in SE Market3.4%

Stable Share Price: ACUC's share price has been volatile over the past 3 months.

Volatility Over Time: ACUC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20063Jonas Jonmarkhttps://www.acucort.com

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

AcuCort AB (publ) Fundamentals Summary

How do AcuCort's earnings and revenue compare to its market cap?
ACUC fundamental statistics
Market capkr42.34m
Earnings (TTM)-kr13.69m
Revenue (TTM)kr6.59m

6.4x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACUC income statement (TTM)
Revenuekr6.59m
Cost of Revenuekr0
Gross Profitkr6.59m
Other Expenseskr20.28m
Earnings-kr13.69m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin100.00%
Net Profit Margin-207.69%
Debt/Equity Ratio0%

How did ACUC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.